(19)
(11) EP 2 324 113 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
04.04.2018 Bulletin 2018/14

(45) Mention of the grant of the patent:
28.02.2018 Bulletin 2018/09

(21) Application number: 09805653.4

(22) Date of filing: 10.08.2009
(51) International Patent Classification (IPC): 
C12N 7/01(2006.01)
C07H 21/00(2006.01)
C07K 14/08(2006.01)
 C07K 14/00(2006.01)
A61K 39/12(2006.01)
(86) International application number:
PCT/US2009/053249
(87) International publication number:
WO 2010/017542 (11.02.2010 Gazette 2010/06)

(54)

VIRUS-LIKE PARTICLES COMPRISING COMPOSITE CAPSID AMINO ACID SEQUENCES FOR ENHANCED CROSS REACTIVITY

VIRUSÄHNLICHE PARTIKEL MIT ZUSAMMENGESETZTEN CAPSIDAMINOSÄURESEQUENZEN FÜR ERHÖHTE KREUZREAKTIVITÄT

PARTICULES SIMILAIRES À UN VIRUS COMPORTANT DES SÉQUENCES D'ACIDES AMINÉS DE CAPSIDE COMPOSITES POUR UNE RÉACTIVITÉ CROISÉE AMÉLIORÉE

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

(30) Priority: 08.08.2008 US 87504 P
19.06.2009 US 218603 P

(43) Date of publication of application:
25.05.2011 Bulletin 2011/21

(60) Divisional application:
18158843.5

(73) Proprietor: Takeda Vaccines, Inc.
Cambridge, MA 02139 (US)

(72) Inventors:
  • RICHARDSON, Charles
    Cambridge, MA 02139 (US)
  • BARGATZE, Robert
    Cambridge, MA 02139 (US)
  • HAYNES, Joel
    Cambridge, MA 02139 (US)
  • STEADMAN, Bryan
    Cambridge, MA 02139 (US)

(74) Representative: Hoffmann Eitle 
Patent- und Rechtsanwälte PartmbB Arabellastraße 30
81925 München
81925 München (DE)


(56) References cited: : 
WO-A1-93/21325
WO-A2-2006/086188
US-A1- 2007 207 526
 WO-A1-2008/042789
US-A- 5 953 727
US-B1- 7 067 638
   
  • Foubert, TR et al.: "Preclinical Development of a Broad Spectrum Norovirus Vaccine.", 2009 AAPS National Biotechnology Conference 6/20/2009 - 6/26/2009 , 23 June 2009 (2009-06-23), XP002663632, Retrieved from the Internet: URL:http://abstracts.aapspharmaceutica.com /ExpoNBC09/CC/forms/attendee/index.aspx?co ntent=sessionInfo&sessionId=150 [retrieved on 2011-11-14]
  • MCBURNEY SEAN P ET AL: "Developing broadly reactive HIV-1/AIDS vaccines: a review of polyvalent and centralized HIV-1 vaccines.", CURRENT PHARMACEUTICAL DESIGN 2007 LNKD- PUBMED:17627529, vol. 13, no. 19, 2007, pages 1957-1964, XP002663633, ISSN: 1873-4286
  • WANG C Y ET AL: "Effective synthetic peptide vaccine for foot-and-mouth disease in swine", VACCINE, ELSEVIER LTD, GB, vol. 20, no. 19-20, 7 June 2002 (2002-06-07), pages 2603-2610, XP004359694, ISSN: 0264-410X, DOI: 10.1016/S0264-410X(02)00148-2
  • MUTHUMANI K ET AL: "Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus", VACCINE, ELSEVIER LTD, GB, vol. 26, no. 40, 14 April 2008 (2008-04-14), pages 5128-5134, XP025349960, ISSN: 0264-410X [retrieved on 2008-04-14]
  • CACHIA P J ET AL: "THE USE OF SYNTHETIC PEPTIDES IN THE DESIGN OF A CONSENSUS SEQUENCEVACCINE FOR PSEUDOMONAS AERUGINOSA", JOURNAL OF PEPTIDE RESEARCH, BLACKWELL PUBLISHING LTD, OXFORD; GB, vol. 52, no. 4, 1 October 1998 (1998-10-01), pages 289-299, XP000781730, ISSN: 1397-002X
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).